New treatments in renal cancer: The AhR ligands

Kidney cancer rapidly acquires resistance to antiangiogenic agents, such as sunitinib, developing an aggressive migratory phenotype (facilitated by c-Metsignal transduction). The Aryl hydrocarbon receptor (AhR) has recently been postulated as a molecular target for cancer treatment. Currently, there...

Descripción completa

Detalles Bibliográficos
Autores: Itkin, Boris, Breen, Alastair, Turyanska, Lyudmila, Sandes, Eduardo Omar, Bradshaw, Tracey D., Loaiza Perez, Andrea Irene
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:Argentina
Institución:Consejo Nacional de Investigaciones Científicas y Técnicas
Repositorio:CONICET Digital (CONICET)
Idioma:inglés
OAI Identifier:oai:ri.conicet.gov.ar:11336/140004
Acceso en línea:http://hdl.handle.net/11336/140004
Access Level:acceso abierto
Palabra clave:AHR
AMINOFLAVONE
BENZOTHIAZOLES
NANOCOMPOUNDS
RENAL CANCER
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
id AR_e57e47532da2d2b0077d6afadb24f2c4
oai_identifier_str oai:ri.conicet.gov.ar:11336/140004
network_acronym_str AR
network_name_str Argentina
repository_id_str
spelling New treatments in renal cancer: The AhR ligandsItkin, BorisBreen, AlastairTuryanska, LyudmilaSandes, Eduardo OmarBradshaw, Tracey D.Loaiza Perez, Andrea IreneAHRAMINOFLAVONEBENZOTHIAZOLESNANOCOMPOUNDSRENAL CANCERhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Kidney cancer rapidly acquires resistance to antiangiogenic agents, such as sunitinib, developing an aggressive migratory phenotype (facilitated by c-Metsignal transduction). The Aryl hydrocarbon receptor (AhR) has recently been postulated as a molecular target for cancer treatment. Currently, there are two antitumor agent AhR ligands, with activity against renal cancer, that have been tested clinically: aminoflavone (AFP 464, NSC710464) and the benzothiazole (5F 203) prodrug Phortress. Our studies investigated the action of AFP 464, the aminoflavone pro-drug currently used in clinical trials, and 5F 203 on renal cancer cells, specifically examining their effects on cell cycle progression, apoptosis and cell migration. Both compounds caused cell cycle arrest and apoptosis but only 5F 203 potently inhibited the migration of TK-10, Caki-1 and SN12C cells as well as the migration signal transduction cascade, involving c-Met signaling, in TK-10 cells. Current investigations are focused on the development of nano-delivery vehicles, apoferritin-encapsulated benzothiazoles 5F 203 and GW610, for the treatment of renal cancer. These compounds have shown improved antitumor effects against TK-10 cells in vitro at lower concentrations compared with a naked agent.Fil: Itkin, Boris. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; ArgentinaFil: Breen, Alastair. University of Nottingham; Estados UnidosFil: Turyanska, Lyudmila. University of Nottingham; Estados UnidosFil: Sandes, Eduardo Omar. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; ArgentinaFil: Bradshaw, Tracey D.. University of Nottingham; Estados UnidosFil: Loaiza Perez, Andrea Irene. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaMolecular Diversity Preservation International2020-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/140004Itkin, Boris; Breen, Alastair; Turyanska, Lyudmila; Sandes, Eduardo Omar; Bradshaw, Tracey D.; et al.; New treatments in renal cancer: The AhR ligands; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 21; 10; 5-2020; 1-201661-65961422-0067CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3390/ijms21103551info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2024-05-08T14:04:10Zoai:ri.conicet.gov.ar:11336/140004instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982024-05-08 14:04:10.446CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv New treatments in renal cancer: The AhR ligands
title New treatments in renal cancer: The AhR ligands
spellingShingle New treatments in renal cancer: The AhR ligands
Itkin, Boris
AHR
AMINOFLAVONE
BENZOTHIAZOLES
NANOCOMPOUNDS
RENAL CANCER
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
title_short New treatments in renal cancer: The AhR ligands
title_full New treatments in renal cancer: The AhR ligands
title_fullStr New treatments in renal cancer: The AhR ligands
title_full_unstemmed New treatments in renal cancer: The AhR ligands
title_sort New treatments in renal cancer: The AhR ligands
dc.creator.none.fl_str_mv Itkin, Boris
Breen, Alastair
Turyanska, Lyudmila
Sandes, Eduardo Omar
Bradshaw, Tracey D.
Loaiza Perez, Andrea Irene
author Itkin, Boris
author_facet Itkin, Boris
Breen, Alastair
Turyanska, Lyudmila
Sandes, Eduardo Omar
Bradshaw, Tracey D.
Loaiza Perez, Andrea Irene
author_role author
author2 Breen, Alastair
Turyanska, Lyudmila
Sandes, Eduardo Omar
Bradshaw, Tracey D.
Loaiza Perez, Andrea Irene
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv AHR
AMINOFLAVONE
BENZOTHIAZOLES
NANOCOMPOUNDS
RENAL CANCER
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
topic AHR
AMINOFLAVONE
BENZOTHIAZOLES
NANOCOMPOUNDS
RENAL CANCER
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
description Kidney cancer rapidly acquires resistance to antiangiogenic agents, such as sunitinib, developing an aggressive migratory phenotype (facilitated by c-Metsignal transduction). The Aryl hydrocarbon receptor (AhR) has recently been postulated as a molecular target for cancer treatment. Currently, there are two antitumor agent AhR ligands, with activity against renal cancer, that have been tested clinically: aminoflavone (AFP 464, NSC710464) and the benzothiazole (5F 203) prodrug Phortress. Our studies investigated the action of AFP 464, the aminoflavone pro-drug currently used in clinical trials, and 5F 203 on renal cancer cells, specifically examining their effects on cell cycle progression, apoptosis and cell migration. Both compounds caused cell cycle arrest and apoptosis but only 5F 203 potently inhibited the migration of TK-10, Caki-1 and SN12C cells as well as the migration signal transduction cascade, involving c-Met signaling, in TK-10 cells. Current investigations are focused on the development of nano-delivery vehicles, apoferritin-encapsulated benzothiazoles 5F 203 and GW610, for the treatment of renal cancer. These compounds have shown improved antitumor effects against TK-10 cells in vitro at lower concentrations compared with a naked agent.
publishDate 2020
dc.date.none.fl_str_mv 2020-05
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/140004
Itkin, Boris; Breen, Alastair; Turyanska, Lyudmila; Sandes, Eduardo Omar; Bradshaw, Tracey D.; et al.; New treatments in renal cancer: The AhR ligands; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 21; 10; 5-2020; 1-20
1661-6596
1422-0067
CONICET Digital
CONICET
url http://hdl.handle.net/11336/140004
identifier_str_mv Itkin, Boris; Breen, Alastair; Turyanska, Lyudmila; Sandes, Eduardo Omar; Bradshaw, Tracey D.; et al.; New treatments in renal cancer: The AhR ligands; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 21; 10; 5-2020; 1-20
1661-6596
1422-0067
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms21103551
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Molecular Diversity Preservation International
publisher.none.fl_str_mv Molecular Diversity Preservation International
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1799195801481641984
score 15.812429

Similares en LA Referencia